Comparing Pazopanib vs Sunitinib
| Pazopanib | Sunitinib |
|
|---|
| Pazopanib | Sunitinib |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Pazopanib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Renal Cell Carcinoma, Gastrointestinal Stromal Tumor, Pancreatic Cancer. Sunitinib may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Pazopanib | More about Sunitinib | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Pazopanib has an average rating of 8.0 out of 10 from a total of 92 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 9% reported a negative effect. |
Sunitinib has an average rating of 7.3 out of 10 from a total of 35 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
View all Pazopanib side effects |
View all Sunitinib side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Pazopanib prices |
View all Sunitinib prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Votrient | Sutent | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
30.9 hours |
60 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 706 drugs are known to interact with Pazopanib:
|
A total of 491 drugs are known to interact with Sunitinib:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
October 19, 2009 |
January 26, 2006 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Votrient
Votrient is used to treat renal cell carcinoma (kidney cancer). Learn about side effects ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Yondelis
Yondelis (trabectedin) is used to treat liposarcoma or leiomyosarcoma, two common subtypes of soft ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Tecentriq Hybreza
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is a subcutaneous formulation of Tecentriq ...
Atezolizumab/hyaluronidase
Atezolizumab/hyaluronidase is used for alveolar soft part sarcoma, hepatocellular carcinoma ...
Atezolizumab
Atezolizumab (Tecentriq) is a type of immunotherapy drug that helps the body's immune system to ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.